<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05045287</url>
  </required_header>
  <id_info>
    <org_study_id>JS2021-6-1</org_study_id>
    <nct_id>NCT05045287</nct_id>
  </id_info>
  <brief_title>Hypofractionated Post Mastectomy Radiation With Two-Stage Expander/Implant Reconstruction</brief_title>
  <official_title>Phase II Study of Hypofractionated Post Mastectomy Radiation With Two-Stage Expander/Implant Reconstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypofractionated radiotherapy could provide more convenient treatment and had similar&#xD;
      toxicities.However,reports of hypofractionated radiotherapy with two-stage expander/implant&#xD;
      reconstruction are rare,Some studies have shown that hypofractionated radiotherapy had&#xD;
      similar toxicities to conventional fractionated radiotherapy in patients with breast&#xD;
      reconstruction. So,investigators conducted a phase II study to observe the reconstruction&#xD;
      failure in hypofractionated radiotherapy with two-stage expander/implant reconstruction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Results from a phase III randomized controlled study in China showed that Postmastectomy&#xD;
      hypofractionated radiotherapy was non-inferior to and had similar toxicities to conventional&#xD;
      fractionated radiotherapy in patients with high-risk breast cancer.However,reports of&#xD;
      hypofractionated radiotherapy with two-stage expander/implant reconstruction are rare.&#xD;
      Literatures report that reconstruction failure is a well-known complication of radiation&#xD;
      therapy in breast cancer patients with reconstruction. Results may vary based on RT timing&#xD;
      and technique. Some studies have shown that hypofractionated radiotherapy had similar&#xD;
      reconstruction failure to conventional fractionated radiotherapy in patients with breast&#xD;
      reconstruction. So,investigators conducted a phase II study to observe the reconstruction&#xD;
      failure in hypofractionated radiotherapy with two-stage expander/implant reconstruction.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 8, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>reconstruction failure</measure>
    <time_frame>12 months after the reconstructive surgery</time_frame>
    <description>the 1-year rate of implant removal due to serious complications (such as infection, hematoma, seromatas, prosthesis exposure, prosthesis rupture, envelope contracture, severe breast deformity, etc.)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cosmetic result</measure>
    <time_frame>12 months after the reconstructive surgery</time_frame>
    <description>Digital photographs will be taken of each patient to facilitate thorough assessment of breast symmetry, cleavage and donor site scarring. Overall satisfaction is scored on a five-point Likert scale (1 = very unhappy, 5 = very happy).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Acute and late radiotherapy toxicity</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Radiotherapy toxicity assessed by CTCAE3 and RTOG standard （e. g. acute skin toxicity, radiation pneumo nitis, etc.)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">57</enrollment>
  <condition>Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>hypofractionated radiation therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>receive chest wall and nodal irradiation at a dose of 43.5 Gy in 15 fractions over 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>hypofractionated radiotherapy</intervention_name>
    <description>Undergo hypofractionated RT，obeserve reconstruction failure，cosmetic result and recurrence rate</description>
    <arm_group_label>hypofractionated radiation therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologic diagnosis of stage I-IIIc invasive breast cancer (ductal, lobular, mammary,&#xD;
             medullary, or ductal)&#xD;
&#xD;
             ≤ T3 or N+&#xD;
&#xD;
          -  negative surgery margins&#xD;
&#xD;
          -  positive postoperative pathologic axillary lymph nodes after neoadjuvant chemotherapy&#xD;
             (ypN+).&#xD;
&#xD;
          -  Undergo mastectomy+expander+RT（hypofractionated radiotherapy）+delayed prosthesis&#xD;
             reconstruction&#xD;
&#xD;
          -  Sign the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  T4,&#xD;
&#xD;
          -  axillary sentinel lymph node biopsy without axillary dissection&#xD;
&#xD;
          -  Recurrent breast cancer or history of prior breast radiation therapy (neck, chest&#xD;
             wall, axilla)&#xD;
&#xD;
          -  Uncontrollable co-morbidities, including but not limited to active collagen vascular&#xD;
             disease (e.g., systemic lupus erythematosus, scleroderma, or dermatomyositis),&#xD;
             persistent or active infection, symptomatic congestive heart failure, unstable angina,&#xD;
             mental illness incapacitating participation in this study&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  History of malignancy other than the following： (At least 5 years of tumor free&#xD;
             survival with a very low risk of recurrence, e.g., carcinoma in situ of the cervix and&#xD;
             basal cell or squamous cell carcinoma of the skin）&#xD;
&#xD;
          -  requiring bilateral breast/chest wall radiation therapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing jin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director of radiotherapy department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ning Li, MD</last_name>
    <phone>010-8778-8221</phone>
    <email>lining@cicams.ac.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jiawei Lu</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518116</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiawei Lu, MMed</last_name>
      <phone>15106203082</phone>
      <email>ljw120920@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Khan AJ, Poppe MM, Goyal S, Kokeny KE, Kearney T, Kirstein L, Toppmeyer D, Moore DF, Chen C, Gaffney DK, Haffty BG. Hypofractionated Postmastectomy Radiation Therapy Is Safe and Effective: First Results From a Prospective Phase II Trial. J Clin Oncol. 2017 Jun 20;35(18):2037-2043. doi: 10.1200/JCO.2016.70.7158. Epub 2017 May 1.</citation>
    <PMID>28459606</PMID>
  </results_reference>
  <results_reference>
    <citation>Fowble B, Park C, Wang F, Peled A, Alvarado M, Ewing C, Esserman L, Foster R, Sbitany H, Hanlon A. Rates of Reconstruction Failure in Patients Undergoing Immediate Reconstruction With Tissue Expanders and/or Implants and Postmastectomy Radiation Therapy. Int J Radiat Oncol Biol Phys. 2015 Jul 1;92(3):634-41. doi: 10.1016/j.ijrobp.2015.02.031. Epub 2015 Apr 28.</citation>
    <PMID>25936815</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang SL, Fang H, Song YW, Wang WH, Hu C, Liu YP, Jin J, Liu XF, Yu ZH, Ren H, Li N, Lu NN, Tang Y, Tang Y, Qi SN, Sun GY, Peng R, Li S, Chen B, Yang Y, Li YX. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2019 Mar;20(3):352-360. doi: 10.1016/S1470-2045(18)30813-1. Epub 2019 Jan 30.</citation>
    <PMID>30711522</PMID>
  </results_reference>
  <results_reference>
    <citation>Santosa KB, Chen X, Qi J, Ballard TNS, Kim HM, Hamill JB, Bensenhaver JM, Pusic AL, Wilkins EG. Postmastectomy Radiation Therapy and Two-Stage Implant-Based Breast Reconstruction: Is There a Better Time to Irradiate? Plast Reconstr Surg. 2016 Oct;138(4):761-769. doi: 10.1097/PRS.0000000000002534.</citation>
    <PMID>27673513</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 24, 2021</study_first_submitted>
  <study_first_submitted_qc>September 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Jing Jin, M.D.</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <keyword>hypofractionated radiotherapy</keyword>
  <keyword>Two-Stage Expander/Implant Reconstruction</keyword>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

